DK3288637T3 - Målretning af nad+ til behandling af kemoterapi- og radioterapi-induceret, kognitiv funktionsnedsættelse, neuropatier og inaktivitet - Google Patents
Målretning af nad+ til behandling af kemoterapi- og radioterapi-induceret, kognitiv funktionsnedsættelse, neuropatier og inaktivitet Download PDFInfo
- Publication number
- DK3288637T3 DK3288637T3 DK16787140.9T DK16787140T DK3288637T3 DK 3288637 T3 DK3288637 T3 DK 3288637T3 DK 16787140 T DK16787140 T DK 16787140T DK 3288637 T3 DK3288637 T3 DK 3288637T3
- Authority
- DK
- Denmark
- Prior art keywords
- neuropathies
- inactivity
- cognitive impairment
- induced cognitive
- radiotherapy induced
- Prior art date
Links
- 208000028698 Cognitive impairment Diseases 0.000 title 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 title 1
- 238000002512 chemotherapy Methods 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 230000007823 neuropathy Effects 0.000 title 1
- 238000001959 radiotherapy Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02012—Nicotinamide phosphoribosyltransferase (2.4.2.12), i.e. visfatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07001—Nicotinamide-nucleotide adenylyltransferase (2.7.7.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153876P | 2015-04-28 | 2015-04-28 | |
| PCT/US2016/029765 WO2016176437A1 (en) | 2015-04-28 | 2016-04-28 | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3288637T3 true DK3288637T3 (da) | 2022-10-17 |
Family
ID=57198851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16787140.9T DK3288637T3 (da) | 2015-04-28 | 2016-04-28 | Målretning af nad+ til behandling af kemoterapi- og radioterapi-induceret, kognitiv funktionsnedsættelse, neuropatier og inaktivitet |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10603334B2 (da) |
| EP (1) | EP3288637B1 (da) |
| JP (2) | JP7193232B2 (da) |
| KR (1) | KR20180006389A (da) |
| CN (2) | CN113244396A (da) |
| AU (1) | AU2016255853B2 (da) |
| CA (1) | CA2984379C (da) |
| DK (1) | DK3288637T3 (da) |
| ES (1) | ES2927894T3 (da) |
| PL (1) | PL3288637T3 (da) |
| PT (1) | PT3288637T (da) |
| WO (1) | WO2016176437A1 (da) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015070280A1 (en) * | 2013-11-14 | 2015-05-21 | Newsouth Innovations Pty Limited | Senescence and senescence associated secretory phenotype |
| CA2984379C (en) | 2015-04-28 | 2024-06-11 | Newsouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity |
| ES2957388T3 (es) | 2016-07-15 | 2024-01-18 | H2 Water Tech Ltd | Composición para producir agua rica en hidrógeno |
| US20200179441A1 (en) * | 2017-04-27 | 2020-06-11 | H2 Water Technologies Ltd. | Synergistic compositions for increasing mitochondrial function and energy |
| CN107213159B (zh) * | 2017-06-05 | 2020-06-23 | 苏州人本药业有限公司 | Nadph在制备抗焦虑药物中的应用 |
| CN107213160B (zh) * | 2017-06-06 | 2020-07-24 | 重庆纳德福实业集团有限公司 | Nadph在拮抗药物致线粒体毒性中的应用 |
| CN107158021A (zh) * | 2017-06-20 | 2017-09-15 | 同济大学 | 烟酰胺腺嘌呤二核苷酸在制备治疗癌性疼痛药物的应用 |
| CN107233352A (zh) * | 2017-06-20 | 2017-10-10 | 同济大学 | 烟酰胺腺嘌呤二核苷酸在制备治疗炎性痛药物中的应用 |
| JP2020526511A (ja) * | 2017-06-30 | 2020-08-31 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシドの合成方法 |
| CN108578403A (zh) * | 2018-01-31 | 2018-09-28 | 南京中医药大学 | 小檗碱用于制备防治化疗诱导的周围神经病变药物的用途 |
| US20200407700A1 (en) * | 2018-02-26 | 2020-12-31 | President And Fellows Of Harvard College | Compositions of parp14 modulators and/or mutants and therapeutic use thereof |
| KR20200144576A (ko) * | 2018-05-17 | 2020-12-29 | 주식회사 헬릭스미스 | 화학요법-유발 말초신경병증과 관련된 신경병증성 통증의 치료 |
| EP3972593B1 (en) * | 2019-05-23 | 2025-07-02 | Board of Regents, The University of Texas System | Inhibitor of mnk for the treatment of neuropathic pain |
| CN110237089A (zh) * | 2019-06-19 | 2019-09-17 | 泓博元生命科技（深圳）有限公司 | Nadh和/或nmn防治男性勃起功能障碍的应用 |
| EP3999518A2 (en) | 2019-07-19 | 2022-05-25 | Biosynth AG | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof |
| CN110507695A (zh) * | 2019-08-20 | 2019-11-29 | 泓博元生命科技（深圳）有限公司 | Nadh和/或nmn在制备脑功能恢复的药物、保健品中的应用 |
| FR3100449B1 (fr) * | 2019-09-09 | 2022-08-26 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes |
| RS65256B1 (sr) * | 2019-09-09 | 2024-03-29 | Nuvamid Sa | Upotreba nmn za prevenciju i/ili lečenje bola i odgovarajuće kompozicije |
| CN112569243A (zh) * | 2019-09-30 | 2021-03-30 | 神农医药科技有限公司 | 制备治疗阿尔茨海默病的药物 |
| CN110974781A (zh) * | 2020-01-02 | 2020-04-10 | 崔立峰 | 一种用于皮肤创面修复的凝胶 |
| FR3106056B1 (fr) * | 2020-01-13 | 2021-12-17 | Nuvamid | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes |
| FR3108031B1 (fr) * | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes |
| FR3108032B1 (fr) * | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes |
| CN115867270A (zh) * | 2020-05-11 | 2023-03-28 | 三得利控股株式会社 | 烟酰胺腺嘌呤二核苷酸（nad）浓度上升剂 |
| US20230270770A1 (en) * | 2020-07-30 | 2023-08-31 | Moises HERNANDEZ-VAZQUEZ | Nutritional supplements for repairing muscle and defending against deterioration from human aging |
| CN112076204A (zh) * | 2020-09-29 | 2020-12-15 | 深圳雾件科技有限公司 | 一种烟酰胺单核苷酸在运动神经元修复的应用 |
| CN114432309A (zh) * | 2020-11-06 | 2022-05-06 | 中国科学院深圳先进技术研究院 | 一种提高烟酰胺磷酸核糖转移酶活性的方法及其组合物 |
| WO2022094916A1 (zh) * | 2020-11-06 | 2022-05-12 | 中国科学院深圳先进技术研究院 | 一种提高烟酰胺磷酸核糖转移酶活性的方法及其组合物 |
| CN112891364A (zh) * | 2021-03-15 | 2021-06-04 | 深圳市新靶向生物科技有限公司 | 一种用于防治细胞受γ射线和中子核辐射损伤的药物 |
| CN114045288A (zh) * | 2021-10-21 | 2022-02-15 | 浙江大学 | 靶向敲降SIRT2基因的shRNA及烟酰胺腺嘌呤二核苷酸的前体在制备治疗神经退行性疾病的药物中的应用 |
| CN113750242A (zh) * | 2021-10-28 | 2021-12-07 | 复旦大学附属中山医院 | Nmn联合cd38抑制剂在制备预防或治疗阿霉素所致心脏毒性药物中的应用 |
| CN116236498A (zh) * | 2021-12-08 | 2023-06-09 | 深圳先进技术研究院 | 二氢烟酰胺核糖和烟酰胺单核苷酸在治疗青春期自伤和恶劣环境因素诱导抑郁中的应用 |
| US12552760B2 (en) | 2022-04-22 | 2026-02-17 | The Board Of Trustees Of The University Of Illinois | Compounds for increasing the nicotinamide adenine dinucleotide in a subject and methods of use thereof |
| CN114807189A (zh) * | 2022-05-27 | 2022-07-29 | 河南大学淮河医院 | 一种增加海马神经元树突分支及树突棘数量的靶基因、药物及应用 |
| WO2024086306A1 (en) * | 2022-10-19 | 2024-04-25 | Vitakey Inc. | Formulated food products |
| EP4615448A1 (en) * | 2022-11-12 | 2025-09-17 | Cambridge Enterprise Limited | Sarm1 agents for use in therapy and cosmetics |
| WO2024201281A1 (en) * | 2023-03-28 | 2024-10-03 | Wonderfeel | Methods and compositions for treatment of pain |
| CN116251089A (zh) * | 2023-04-24 | 2023-06-13 | 安徽科技学院 | 一种改善抑郁症的组合物及其在保健品、食品或药物中的应用 |
| CN121152567A (zh) | 2023-05-12 | 2025-12-16 | 明治控股股份有限公司 | 用于促进儿童的发育的组合物 |
| WO2024258622A1 (en) * | 2023-06-13 | 2024-12-19 | Alkahest, Inc. | Blood plasma fractions as a treatment for chemotherapy induced cognitive disorders |
| CN118319935A (zh) * | 2024-04-17 | 2024-07-12 | 音芙医药科技(上海)有限公司 | 一种还原型β-烟酰胺单核苷酸的药物用途 |
| EP4643856A1 (en) * | 2024-05-03 | 2025-11-05 | Centre National de la Recherche Scientifique | Carbazole derivatives used as neuroprotectants and in the treatment of disorders with reduced nad metabolism |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| WO1999033792A2 (en) | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| AU2012199A (en) | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
| EA200000702A1 (ru) | 1997-12-24 | 2000-12-25 | Вертекс Фармасьютикалз Инкорпорейтед | Пролекарства ингибиторов аспартилпротеаз |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| CN1213747C (zh) | 2000-03-03 | 2005-08-10 | 李叔文 | 爱滋病特效药 |
| US7012086B1 (en) | 2000-06-30 | 2006-03-14 | The Foundation For Innovative Therapies, Inc. | Treatment of retrovirus induced derangements with niacin compounds |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| CN1964627B (zh) * | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| DK1824470T3 (da) | 2004-12-17 | 2014-08-18 | Cash Alan Brian | Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom |
| EP2805719A1 (en) * | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| CN100348202C (zh) | 2005-04-28 | 2007-11-14 | 刘朝雄 | 一种治疗皮肤病的口服复方制剂 |
| US7737158B2 (en) | 2005-10-11 | 2010-06-15 | Washington University | Processes for regulating blood glucose in a mammal |
| CN101360421B (zh) | 2005-11-18 | 2014-06-18 | 康乃尔研究基金会有限公司 | 烟酰核苷组合物及其使用方法 |
| US8148338B2 (en) | 2006-02-22 | 2012-04-03 | Supratek Pharma Inc. | Doxorubicin formulations for anti-cancer use |
| US7745487B2 (en) | 2006-07-17 | 2010-06-29 | Quercegen Pharma Llc | Method for enhancing physical performance or immune system recovery from intense physical excercise with quercetin-containing compositions |
| WO2009108999A1 (en) | 2008-03-03 | 2009-09-11 | Ross Stewart Grant | Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
| CA2717915A1 (en) | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| CA2748813C (en) | 2009-01-09 | 2018-07-10 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US20110052676A1 (en) | 2009-09-01 | 2011-03-03 | James Vincent Gruber | Composition For Delaying Cellular Senescence |
| MX2012003212A (es) * | 2009-09-17 | 2012-09-07 | North Texas Medical Ass | Papel del acido n-2-hidroxi-etil-piperazina-n´-2-etano sulfonico (hepes) en el control del dolor y reversion de lesiones por desmielinizacion. |
| WO2012068539A1 (en) | 2010-11-19 | 2012-05-24 | Limerick Biopharma, Inc. | Use and composition of quercetin-3'-o-sulfate for therapeutic treatment |
| US20120328526A1 (en) | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| MX2014007093A (es) | 2011-12-13 | 2014-10-13 | Buck Inst For Res On Aging | Metodos para mejorar terapias medicas. |
| CN102631385A (zh) | 2012-05-10 | 2012-08-15 | 西北农林科技大学 | 一种复方槲皮素纳米乳抗衰老保健品 |
| KR101435717B1 (ko) | 2012-09-06 | 2014-09-01 | 영남대학교 산학협력단 | 퀘세틴-3-Ｏ-β-Ｄ-글루쿠로니드를 유효성분으로 함유하는 세포 노화 억제용 조성물 |
| CN102973461A (zh) | 2012-11-30 | 2013-03-20 | 汤燕 | 保湿润肤且可延缓衰老的化妆用复合物 |
| US20150352094A1 (en) | 2013-01-07 | 2015-12-10 | Catabasis Pharmaceuticals, Inc. | Use of fatty acid niacin conjugates for treating diseases |
| US20140271812A1 (en) * | 2013-03-14 | 2014-09-18 | Panacea Pharmaceuticals | Treatment for chemotherapy-induced cognitive impairment |
| WO2015070280A1 (en) | 2013-11-14 | 2015-05-21 | Newsouth Innovations Pty Limited | Senescence and senescence associated secretory phenotype |
| CA2984379C (en) | 2015-04-28 | 2024-06-11 | Newsouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity |
-
2016
- 2016-04-28 CA CA2984379A patent/CA2984379C/en active Active
- 2016-04-28 ES ES16787140T patent/ES2927894T3/es active Active
- 2016-04-28 JP JP2017556614A patent/JP7193232B2/ja active Active
- 2016-04-28 EP EP16787140.9A patent/EP3288637B1/en active Active
- 2016-04-28 KR KR1020177034001A patent/KR20180006389A/ko not_active Ceased
- 2016-04-28 WO PCT/US2016/029765 patent/WO2016176437A1/en not_active Ceased
- 2016-04-28 PL PL16787140.9T patent/PL3288637T3/pl unknown
- 2016-04-28 AU AU2016255853A patent/AU2016255853B2/en active Active
- 2016-04-28 US US15/570,210 patent/US10603334B2/en active Active
- 2016-04-28 PT PT167871409T patent/PT3288637T/pt unknown
- 2016-04-28 CN CN202110362145.6A patent/CN113244396A/zh active Pending
- 2016-04-28 CN CN201680037951.3A patent/CN108025187A/zh active Pending
- 2016-04-28 DK DK16787140.9T patent/DK3288637T3/da active
-
2020
- 2020-02-14 US US16/790,965 patent/US11389469B2/en active Active
-
2021
- 2021-01-08 JP JP2021001774A patent/JP2021073207A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20200405736A1 (en) | 2020-12-31 |
| CN108025187A (zh) | 2018-05-11 |
| JP2018514548A (ja) | 2018-06-07 |
| KR20180006389A (ko) | 2018-01-17 |
| US20180125871A1 (en) | 2018-05-10 |
| EP3288637B1 (en) | 2022-09-14 |
| EP3288637A1 (en) | 2018-03-07 |
| CA2984379A1 (en) | 2016-11-03 |
| US10603334B2 (en) | 2020-03-31 |
| AU2016255853B2 (en) | 2021-08-05 |
| US11389469B2 (en) | 2022-07-19 |
| JP7193232B2 (ja) | 2022-12-20 |
| PT3288637T (pt) | 2022-10-11 |
| CA2984379C (en) | 2024-06-11 |
| ES2927894T3 (es) | 2022-11-11 |
| PL3288637T3 (pl) | 2022-12-19 |
| EP3288637A4 (en) | 2019-02-13 |
| AU2016255853A1 (en) | 2017-11-30 |
| JP2021073207A (ja) | 2021-05-13 |
| WO2016176437A1 (en) | 2016-11-03 |
| CN113244396A (zh) | 2021-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3288637T3 (da) | Målretning af nad+ til behandling af kemoterapi- og radioterapi-induceret, kognitiv funktionsnedsættelse, neuropatier og inaktivitet | |
| EP3344624A4 (en) | Tyk2 inhibitors and uses thereof | |
| IL258900A (en) | Treatment of small cell lung cancer with a parp inhibitor | |
| EP3368656A4 (en) | TARGETED CANCER THERAPY | |
| DK3277842T3 (da) | Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer | |
| MA41598A (fr) | Composés thérapeutiques de pyridazine et leurs utilisations | |
| DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| LT3253865T (lt) | Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą | |
| DK3359241T3 (da) | Formuleringer af pthrp-analoger, transdermale plastre deraf og anvendelser deraf | |
| PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
| EP3325488A4 (en) | CHIRAL DIARYLMA CROCYCLES AND USES THEREOF | |
| DK2943192T3 (da) | Fremgangsmåder til behandling af pancreascancer, hvilke fremgangsmåder omfatter paclitaxel og gemcitabin | |
| DK3262066T4 (da) | Genterapi | |
| DK3212340T3 (da) | Blødt og modstandsdygtigt, ballistisk panser | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| PL3612624T3 (pl) | Terapia genowa | |
| MX2015011606A (es) | Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer. | |
| HUE038541T2 (hu) | Rák kezelési módszerek | |
| EP3334429C0 (en) | HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| EP3429626A4 (en) | COMBINATION THERAPY WITH A LIV1 ADC AND A CHEMOTHERAPEUTIC | |
| PT3612237T (pt) | Terapia genética | |
| IL269544A (en) | Optimization of enzyme replacement therapy for treatment of homocystinuria | |
| LT3268480T (lt) | Priemonės ir būdai, skirti panaudoti ląstelių dalijimosi lokusus ląstelių proliferacijos kontroliavimui |